2nd European Conference on Oncology Cancer Therapy

Sep 29-30, 2021

|

Online Webinar



ABOUT CONFERENCE

Oncology 2021 is a trending event that brings together efficient international academic scientists, young researchers, students and experts in the field of “ Oncology Cancer Therapy  making the conference a perfect platform to share experiences, gain and evaluate emerging technologies of Cancer & Oncology across the globe. Initiation of cross-border co-operations between scientists and institutions also provides a premier interdisciplinary platform for researchers, practitioners, and educators to present and discuss the most recent innovations, trends, and concerns and practical challenges encountered and solutions adopted in the fields of Cancer & Oncology. The collaborations among the participants from various countries at the conference will generate knowledge-based research among radiology and researchers.

The Theme Edifying  "Explore the Latest Innovative treatment of Oncology and Cancer Challenges" will give an invigorating logical climate and a stage for the members to share thoughts and information, work together on Cancer and Oncology related developments, issues with different experts. Talking about different basic themes will add an understanding to examine and talk over the main concern of the present logical and mechanical liven up. It will be an astounding open door for the participants to investigate the excellent Netherlands with acquiring information, sure to raise bits of knowledge, amalgamate present with future and consider on thoughts and reality at the gathering. Oncology 2021 has shown this drive to investigate each part of Cancer and Oncology

TARGET AUDIENCE   

  • Students
  • Research Scholars
  • Scientists
  • Young Researchers
  • Doctors
  • Digital medicine and therapeutic companies
  • Pharm, biotech, and tech companies
  • Health care industries
  • Buy and sell-side analysts
  • Biotechnology researchers
  • Professors
  • Oncologist

Why attend???

This is your best opportunity to reach the largest assemblage of participants from the Cancer & Oncology community. Live Events -- which include Keynote Sessions, Speaker Sessions, and Poster Presentations Video Presentations; provides a unique approach for learning and career building. Attendees will be having an Oncology Cancer Therapy Conference as Delegates, Academics, and Experts in Oncology Cancer Therapy across the globe.

MARKET ANALYSIS

The oncology market size was valued at $136.7 billion in 2019 and is poised to grow at a CAGR of 11.9% during the forecast period 2020-2025. Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer. Cancer is a disease, which involves the abnormal growth of cells that result in the formation of a tumour. However, a benign tumour is not cancers. The abnormal tumour cells tend to spread to other local tissues and different parts of the body through the blood and lymphatic system. Treatment of cancer depends upon the stages of the disease progression. Increased prevalence of cancer, unhealthy lifestyle and increasing geriatric population are the primary factors driving the growth of the oncology market. High market growth potential in developing nations, a rise in the number of pipeline products, and the upsurge in demand for personalized medicines are poised to create new opportunities for the market players during the forecast period 2020-2025.

  • In 2019, North America dominated the Oncology Market owing to emerging biopharma companies in U.S and Canada.
  • Emerging bio pharmacy companies in the U.S. for oncology and the growing concern of people towards health are contributing to the growth of the oncology market.
  • Pharma companies that are active in oncology are now in a race to harness new data sources and digital platforms, so they can engage patients, providers, and regulators more effectively, and creating an increase in demand.
  • Detailed analysis on the Strength, Weakness and opportunities of the prominent players operating in the market will be provided in the Oncology Market Report

 

 

Lucy
Dr Babak Abdolkarimi
Assistant professor
Hematology oncology
Lorestan University of Medical Sciences. khoramabad, Iran

Biography

Brain tumours are the second common neoplasms in children, after leukaemias.

Some brain tumours are unresectable, which are located in an inaccessible place in the brain, for surgeons or remove it and surgery may have to destroy or damage nearby healthy brain tissue or cause mortality or severe morbidities such as speech or movement dysfunction.

 The surgeon determines if a patient's brain tumour is inoperable, so it is advisable to seek a second approach such as stereotactic radiosurgery or palliative conventional chemotherapy or radiation therapy, but there isn't,t  new radiosurgery method in developing countries or conventional cytotoxic therapy haven,t sufficient efficacy. Metronomic chemotherapy is an unexpensive way to regress inoperable brain tumours such as ependymoma, brainstem glioma, and medulloblastoma and destroy inoperable tumours with different mechanisms.

 

Anti-angiogenesis effect is common mechanisms of metronomic chemotherapy while prominently decreasing undesirable toxic adverse effects can use for inhibiting unresectable solid tumours, but the main mechanism against inoperable tumours is immuno-surveillance intensification especially T cells (TREG) inhibition.

TREG can inhibit the anti-tumour immune response by suppressing the activity of both tumour-specific (CD8+ cytotoxic T lymphocytes and CD4+ T helper cells) and tumour-unspecific effector cells (natural killer [NK] and NK T cells.

Increased frequency of TREG cells can correlate with tumour progression and loss of treatment response. ( 5)  Moreover, impairment of TREG activity by either specific blockade or depletion can enhance the immune response against tumour-associated antigens.

A sample metronomic regimen for meduloblastoma include:

1.Celecoxib 250 mg/m2 PO b.i.d  day 1 to 43

2.Etoposide   50 mg/m2  po(21 days) plus

3.  Cyclophosphamide 2.5 mg/kg/d po day 22 to 43

4. Fenofibrate(90 mg/m2/d) day 1 to 43

5. Thalidomide (6–12 mg/kg po every day;    maximum daily dose 800 mg) day 1 to 43

6.Bevacizumab 10mg/kg weekly day 15 to 29

7.liposomal Cytarabine 25-50 mg intraventricular every 4 week day 29

For a median of 15.4 months

Description: E:\مقالات\مقالات چاپ شده\metronomic chemotherap[yمقاله\کموتراپی پروتوکلها metronomic\شکلها\figure 1.PNG

Although complete responses stay rare, these solutions mainly lead to long-term disease stabilization and significant improvement in the quality of life among children with inoperable brain tumours.

 Despite clinical success in adults the administration of metronomic treatments in pediatric oncology is still in its early stage as a result of the lack of state-of-the-art clinical studies clearly demonstrating efficacy, but this approach is an inexpensive option in developing countries.

Keywords: metronomic chemotherapy, inoperable brain tumours

Researches :

  • Hematology oncology

Program Overview

Our Collaborations, Sponsors, Media Partners